|
|
Lantheus Holdings Inc (NASDAQ: LNTH) |
|
Price: $100.7300
$0.41 
0.409%
|
| Day's High:
| $100.7699966430664
| Week Perf:
| 0.03 %
|
| Day's Low: |
$ 100.33 |
30 Day Perf: |
-0.22 % |
| Volume (M): |
1,137,526 |
52 Wk High: |
$ 111.86 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$79.17 |
| Open: |
$100.46 |
52 Wk Low: |
$49.67 |
|
|
| Market Capitalization (Millions $) |
6,801 |
| Shares
Outstanding (Millions) |
68 |
| Employees |
1,193 |
| Revenues (TTM) (Millions $) |
1,555 |
| Net Income (TTM) (Millions $) |
275 |
| Cash Flow (TTM) (Millions $) |
-197 |
| Capital Exp. (TTM) (Millions $) |
25 |
Business Description
Lantheus Holdings Inc.
is a publicly traded diagnostics and imaging company based in North Billerica, Massachusetts.
It was formerly known as Bristol-Myers Squibb Medical Imaging and was spun off as a separate entity in 2008.
Lantheus Holdings specializes in the development, production, and distribution of diagnostic imaging agents used in medical imaging, such as ultrasound, nuclear medicine, and magnetic resonance imaging (MRI).
The company's flagship product is DEFINITY, an echocardiography agent that enhances the accuracy and clarity of ultrasound images of the heart.
The company has a global presence, with offices and facilities located in the United States, Canada, Australia, and Puerto Rico.
It also has a robust network of distribution partners and collaborations with other healthcare companies, academic institutions, and research organizations working toward advancing diagnostic imaging.
In recent years, Lantheus Holdings has expanded its product portfolio through acquisitions and partnerships with other companies, including the acquisition of Progenics Pharmaceuticals in 2019.
The company's primary focus is on improving patient outcomes through the development and commercialization of innovative diagnostic agents and technologies.
Company Address: 201 Burlington Road, South Building Bedford 1730 MA
Company Phone Number: 671-8001 Stock Exchange / Ticker: NASDAQ LNTH
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Announcement
Published Wed, Nov 5 2025 4:25 PM UTC
In a significant development for Lantheus Holdings, Inc. (NASDAQ: LNTH), the Portnoy Law Firm has announced a class-action lawsuit on behalf of investors who purchased the company s securities between February 26, 2025, and August 5, 2025. The Los Angeles-based law firm advises investors to file a lead plaintiff motion by the swiftly approaching deadline of November 10, 2025...
|
| Announcement
Published Fri, Sep 19 2025 1:39 AM UTC
In a recent notice from The Gross Law Firm, shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH) were reminded of an urgent deadline to join a class-action lawsuit against the company, set for November 10, 2025. As investors weigh their options, it is essential to consider the company s recent performance indicators alongside the legal proceedings.For the second quarter of...
|
| Announcement
Published Mon, Sep 8 2025 9:09 AM UTC
In an unfolding situation that has caught the attention of the investment community, Lantheus Holdings, Inc. (NASDAQ: LNTH) finds itself under the investigative lens of the Pomerantz Law Firm. The firm is probing claims on behalf of investors who may have been adversely affected by the company’s recent performance, which has raised eyebrows in light of contrasting results ...
|
| Clinical Study
Published Thu, Jun 12 2025 10:13 AM UTC
In a significant stride for the field of nuclear medicine, Lantheus Holdings, Inc., a leading radiopharmaceutical company, has announced the presentation of promising new data at the upcoming 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. Scheduled for June 21-24 in New Orleans, Louisiana, this year s meeting highlights Lantheus s commitment t...
|
| Merger and Acquisition
Published Tue, Apr 1 2025 1:00 PM UTC
BEDFORD, Mass. April 1, 2025 — In a significant move projected to reshape the landscape of radiopharmaceuticals, Lantheus Holdings, Inc. (NASDAQ: LNTH), has finalized its acquisition of Evergreen Theragnostics, Inc. a clinical-stage company specializing in innovative diagnostic and therapeutic radiopharmaceuticals. This transaction, first announced on January 28, 2025, not...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
4.11 $ |
| Revenues (TTM) |
23.04 $
|
| Cash Flow (TTM) |
- |
| Cash |
8.79 $
|
| Book Value |
19.43 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
1,303,724 |
| Net
Income per Employee (TTM) |
230,767 |
| Receivable Turnover Ratio (TTM) |
4.39 |
| Inventory Turnover Ratio (TTM) |
10.09 |
| Asset Turnover Ratio (TTM) |
0.68 |
|
|
| Per Share |
|
| Earnings (TTM) |
4.11 $
|
| Revenues (TTM) |
23.04 $ |
| Cash Flow (TTM) |
- |
| Cash |
8.79 $
|
| Book Value |
19.43 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Product |
|
 192.38 % |
of total Revenue |
| Licenseand Royalty Revenues |
|
4.83 % |
of total Revenue |
| PYLARIFY |
|
123.99 % |
of total Revenue |
| Oncology |
|
123.99 % |
of total Revenue |
| Neuraceq |
|
19.34 % |
of total Revenue |
| Neurology |
|
19.34 % |
of total Revenue |
| DEFINITY |
|
44.54 % |
of total Revenue |
| Cardiology |
|
44.54 % |
of total Revenue |
| Strategic Partnerships and Other |
|
9.34 % |
of total Revenue |
| US |
|
186.18 % |
of total Revenue |
| Non Us |
|
11.02 % |
of total Revenue |
|
|
3.26% 